Business
Celldex is a biopharma company focused on mast-cell biology and therapeutic antibodies for severe inflammatory, allergic, autoimmune, and related diseases.
Celldex advanced its pipeline while loss and cash burn widened.
The read at a glance✓ Audited against SEC data
- Business mix — Mast-cell antibody pipelineNote
- Revenue — $1.5M, -78.0%Watch
- Net loss — $258.8M, widerWatch
- FCF — ($213.7M), weakerWatch
- Equity — $527.2M, -29.4%Watch
- Altman/Beneish/EQ — Weak Z; EQ greyWatch
- Insiders — 0 purchases / 3 salesWatch
Where the revenue comes from
Fiscal 2025, as Celldex Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Grant$1.4M
- Service$97K
Latest filings
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-07-15
- 8-K · Company announcement2026-06-26
- 10-Q · Quarterly report2026-05-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Celldex Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.